Who are Placebo to Denosumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DMAB Discontinuation and Switching, Denosumab (Prolia), Xgeva®, Denosumab Prefilled Syringe [Prolia], Denosumab-Ref, MB09 (denosumab biosimilar).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-denosumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo to Denosumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to Denosumab (Placebo to Denosumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANKL inhibitor (monoclonal antibody). Area: Bone metabolism / Osteoporosis.

marketed RANKL inhibitor (monoclonal antibody) RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) Bone metabolism / Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to Denosumab (Placebo to Denosumab) — Amgen. Denosumab is a monoclonal antibody that binds to RANKL (receptor activator of nuclear factor kappa-B ligand) and prevents bone resorption by inhibiting osteoclast formation and activation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo to Denosumab TARGET	Placebo to Denosumab	Amgen	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
DMAB Discontinuation and Switching	DMAB Discontinuation and Switching	University of Alabama at Birmingham	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab (Prolia)	Denosumab (Prolia)	Prince of Wales Hospital, Shatin, Hong Kong	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (receptor activator of nuclear factor kappa-B ligand)
Xgeva®	Xgeva®	Jiangsu Hansoh Pharmaceutical Co., Ltd.	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab Prefilled Syringe [Prolia]	Denosumab Prefilled Syringe [Prolia]	Seoul National University Bundang Hospital	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Denosumab-Ref	Denosumab-Ref	Lambda Therapeutic Research Ltd.	phase 3	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
MB09 (denosumab biosimilar)	MB09 (denosumab biosimilar)	mAbxience Research S.L.	phase 3	RANKL inhibitor (monoclonal antibody)	RANKL (receptor activator of nuclear factor kappa-B ligand)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANKL inhibitor (monoclonal antibody) class)

Amgen · 5 drugs in this class
Swiss Cancer Institute · 2 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 1 drug in this class
Lambda Therapeutic Research Ltd. · 1 drug in this class
Luye Pharma Group Ltd. · 1 drug in this class
Prince of Wales Hospital, Shatin, Hong Kong · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class
University of Alabama at Birmingham · 1 drug in this class
mAbxience Research S.L. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to Denosumab — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-denosumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab